Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.

[1][2] This drug was developed by Genentech/Roche.

Development was discontinued in 2017.

[3] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.